Collectively, these results suggested that hepatic Zbtb18 expression inhibited NLRP3 inflammasome’s activation in macrophages via an FXR-mediated CLTC protein expression, which helped mitigate NAFLD in mice. The gene discussed is ZBTB18; the disease is metabolic dysfunction-associated steatotic liver disease.